AdisInsight: Drugs

AdisInsight: Drugs (formerly Adis R&D Insight) provides leading, evidence-based scientific and market information on drugs in commercial development worldwide. Drug and cell-based products are tracked across all therapeutic areas and throughout the entire development process, from discovery to launch.

AdisInsight drug profiles are lengthy full-text reports organized into the following sections:

- Key development milestones
- Development status and history
- Drug properties
- Chemical synopses
- Generic name, synonyms, brand names
- Pharmacokinetics data
- Pharmacodynamics data
- Company agreements
- Trial landscape and details
- Related safety reports
- Patent information
- Related drugs
- Drug limitations
- Immunogenicity
- Developing companies
- Forecasts of approval probability

Data is collected from more than 2,300 biomedical journals covering drugs and therapeutics, news services, newsletters, company annual reports, contact with companies, market intelligence, meetings and conferences.

AdisInsight profiles are also backed by more than 10,000 evaluated Adis scientific summaries and 63,000 bibliographic references.

Use AdisInsight: Drugs to answer such questions as:

- What pipeline reports are available on nivolumab?
- Where is TSR 042 being developed? For which indications?
- Which drugs indicated for glioblastoma are in Phase III in France?
- Which drugs is Celgene developing?
- Which drugs indicated for acne are in highest phase I?

Date Coverage

1995–present

Update Frequency

Weekly

Geographic Coverage

International

Document Types

Reports

Publisher

AdisInsight is produced by SpringerNature.

Last revised: 2 December 2020

AdisInsight: Drugs

Full text « Back to results

Add to selected items | Order full text | Save to My Research | Em

Ipilimumab - Bristol-Myers Squibb

TI

AdisInsight: Drugs. (Nov 21, 2020).

PD

Highlighting: Off | Single | Multi

Full Text Translate

TX

DRUG PROFILE - Ipilimumab - Bristol-Myers Squibb

Ipilimumab is a recombinant, human anti-CTLA-4 monoclonal antibody that activates the immune system by targeting CTLA-4, a protein receptor that down regulates the immune system, being developed by by Bristol-Myers Squibb for treatment of cancer. The agent originated from Medarex, which was later acquired by Bristol-Myers Squibb. The drug has been launched worldwide, for treatment of patients with malignant melanoma. The drug is available in combination with nivolumab for the treatment of hepatocellular carcinoma in patients who have been previously treated with sorafenib. The drug is approved as a combination therapy with nivolumab for malignant melanoma in Japan and South Korea, for metastatic renal cell carcinoma in the US and Canada, for colorectal cancer in Japan, and is awaiting regulatory approval for colorectal cancer in the US. The drug is registered as monotherapy for the treatment of malignant melanoma in the EU, Iceland, Norway, Liechtenstein, Japan and Taiwan. Ipilimumab is approved in the European Union, Norway, Iceland, Liechtenstein and Japan for combination and first-line therapy in patients with metastatic renal cell carcinoma. The drug is available in US for nivolumab plus ipilimumab combination for the first-line treatment of metastatic non-small cell lung cancer and malignant pleural mesothelioma. The drug is approved in the EU as a combination and first-line therapy for non-small cell lung cancer. The drug is under regulatory review in the EU for nivolumab plus ipilimumab combination for the first-line treatment of metastatic Non-small cell lung cancer, in the US for renal cell carcinoma and in Australia, Canada, Brazil and Switzerland for malignant pleural mesothelioma. Clinical development is underway for various types of cancer including adrenocortical carcinoma, breast cancer, CNS cancer, carcinomatous-meningitis, colorectal cancer, gastric cancer, gastrointestinal cancer, genitourinary disorders, glioblastoma, gynaecological cancer, head and neck cancer, hepatocellular carcinoma, liver cancer, lung cancer, mesothelioma, diffuse large B-cell lymphoma, myelodysplastic syndromes, neuroendocrine tumours, non-small cell lung cancer, solid tumours, oesophageal cancer, ovarian cancer, pancreatic cancer, penile cancer, prostate cancer, renal cell cancer in several countries.

(...)

Development Phases

TX, PHS

Phase	Country	Indication	Route of Administration	Formulation	On Fast Track	Qualifiers and Comments
Marketed	Argentina	Malignant-melanoma	IV	Infusion	false	Late-stage disease, Second-line therapy or greater
Marketed	Australia	Malignant-melanoma	IV	Infusion	false	Late-stage disease, Second-line therapy or greater
Marketed	Austria	Malignant-melanoma	IV	Infusion	false	Late-stage disease, Metastatic disease, Second-line therapy or greater
Marketed	Belgium	Malignant-melanoma	IV	Infusion	false	Late-stage disease, Metastatic disease, Second-line therapy or greater
Marketed	Canada	Malignant-melanoma	IV	Infusion	false	Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, In combination with nivolumab

(...)

Indexing (details) Cite

RF, CTI, CAU, CPUB, CYR, CVO **References**

1. Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody blockade in patients previously vaccinated with irradiated, autologous tumor cells engineered to secrete granulocyte-macrophage colony stimulating factor (GM-CSF). Hodi FS, Seiden M, Butler M, Haluska FG, Lowy I, et al.. 40th Annual Meeting of the American Society of Clinical Oncology. : 172, Jun 2004, Language: English, Country: USA (Adis Number: 800982695);
2. Tumor regression in patients with metastatic renal cancer treated with a monoclonal antibody to CTLA4 (MDX-010). Yang JC, Beck KE, Blansfield JA, Tran KQ, Lowy I, et al.. Journal of Clinical Oncology. 23 (Suppl.): 166 (plus oral presentation) abstr. 2501, No. 16, Part I, 1 Jun 2005, Language: English, Country: USA (Adis Number: 800994676);
3. CTLA-4 blockade-based immunotherapy for hormone-refractory prostate cancer. Kavanagh B, Rini B, Weinberg V, Shaw V, Small E, Fong L. 2006 Prostate Cancer Symposium. : abstr. 255, 24 Feb 2006, Language: English, Country: Unknown (Adis Number: 801036744);
4. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. Clinical cancer research: an official journal of the American Association for Cancer Research. 13: 1810-1815, No. 6, 15 Mar 2007, Language: English, Country: USA (Adis Number: 801077655);

SU **Subject**: Monoclonal-antibodies

SUBST **Substance**:
Substance: Immunoglobulin G1, anti-(human CTLA-4 (antigen)) (human γ1-chain), disulphide with human κ-chain, dimer
CAS: 477202-00-9

SYN **Drug synonym**: Anti CTLA-4 monoclonal antibody - Medarex, BMS 734016, BMS-734016, BMS734016, MDX 010, MDX CTLA-4, MDX CTLA4, MDX-010, MDX-CTLA-4, MDX-CTLA4

MF **Molecular formula**: C6472H9972N1732O2004S40

GN **Generic name**: Ipilimumab - Bristol-Myers Squibb

ORD **Orphan drug**:
Indication: Malignant-melanoma
Region: USA
Company: Bristol-Myers Squibb

TN **Trade name**:
Yervoy® (Malignant-melanoma, Australia, Bristol-Myers Squibb)
Yervoy® (Malignant-melanoma, Canada, Bristol-Myers Squibb)
Yervoy® (Malignant-melanoma, Europe, Bristol-Myers Squibb)
Yervoy® (Malignant-melanoma, USA, Bristol-Myers Squibb)

OS **Origin of substance**: Fixed combination: No

RO **Route of administration**: IV, Parenteral, SC

MEC **Mechanism of action**: Cytotoxic-T-lymphocyte-antigen-4-inhibitors, Immunomodulators

PK **Pharmacokinetics**:
Cl (L/h), unspecified, .015 - .015
t (1/2) beta (h), unspecified, 12.500 - 12.500
tmax (h) [oral], unspecified, 1.900 - 1.900

TC **Therapeutic class**:
L1G: Monoclonal Antibody Antineoplastics
L01X-C11: Ipilimumab

IND	**Indication**	Adrenocortical-carcinoma Breast-cancer Cancer Carcinomatous-meningitis Chronic-lymphocytic-leukaemia Chronic-myeloid-leukaemia CNS-cancer Colorectal-cancer Gastric-cancer Gastrointestinal-cancer Genitourinary-disorders Glioblastoma Gynaecological-cancer Head-and-neck-cancer Hepatocellular-carcinoma HIV-infections Liver-cancer Lung-cancer Lymphoma Malignant-melanoma Mesothelioma Myelodysplastic-syndromes Myelofibrosis Myeloid-leukaemia Neuroendocrine-tumours Non-small-cell-lung-cancer Oesophageal-cancer Ovarian-cancer Pancreatic-cancer Penile-cancer Prostate-cancer Renal-cell-carcinoma Small-cell-lung-cancer Solid-tumours Thyroid-cancer Urogenital-cancer
DST	**Drug status**	Active
CO, DOR, LCO	**Company information**	Name: Aduro BioTech, Public, Not-Large-Pharma Type: Biotechnology Role: Collaborator Region: USA Name: AIO Studien gGmbH, Private, Not-Large-Pharma Type: ContractResearchOrganization Role: Collaborator Region: Germany Name: Australia and New Zealand Melanoma Trials Group, Public, Not-Large-Pharma Type: Institution Role: Collaborator Region: Australia Name: Australian and New Zealand Urogenital and Prostate Cancer Group, Not-Large-Pharma Type: Unknown Role: Collaborator Region: Australia Name: Bavarian Nordic, Public, Not-Large-Pharma Type: Biopharmaceutical Role: Collaborator Region: Denmark Name: Big Ten Cancer Research Consortium, Private, Not-Large-Pharma Type: Unknown Role: Collaborator Region: USA

(...)

TI	**Title**	Ipilimumab - Bristol-Myers Squibb
HP	**Highest phase**	Marketed
LG	**Language**	English
DTYPE	**Document type**	Report
PUB	**Publication title**	AdisInsight: Drugs
PSTYPE	**Publication type**	Reports
PD	**Publication date**	Mar 22, 2018
DCRE	**Date created**	1996-05-21
DREV	**Date revised**	2018-03-22
	Source attribution	AdisInsight: Drugs, © Publisher specific
AN	**Accession number**	6680
	Document URL	https://2018r2nightly.aa1.proquest.com/professional/docview/16341325?accountid=100557
FAV	**First available**	2011-11-11
UD	**Updates**	2012-07-30 2016-10-10 2018-03-22 2018-03-28
	Database	AdisInsight: Drugs; 1995 to date (1995 - current)

Search Fields

You can use field codes on the Basic Search, Advanced Search, and Command Line Search pages to limit searches to specific fields. The table below lists the field codes for this database.

Field name	Field code	Example	Description and Notes
Accession number	AN	an(25524)	A unique document identification number assigned by the information provider.
All fields	ALL	all(rupacarib AND preregistration)	Searches all fields *except* the full text
All fields + text	--	rupacarib NEAR preregistration “poly adp ribose polymerase”	Searches all fields including the full text. Use proximity and/or Boolean operators to narrow search results. Use double quotes to specify an exact phrase.
CAS® Registry number	RN	rn(283173-50-2)	The CAS Registry number is also searchable using the Substance field code SUBST.
Classification			See Therapeutic classification
Company[1]	CO	co(astrazeneca) co(“clovis oncology”)	Company names with their type, role (e.g. orginator, licensee) and region are presented. Search Originator with field code DOR, Licensee with LCO or any company role with CO.
Country of launch/development	CLD	cld(brazil)	The country of launch is displayed in the ”Development Phase” section of the text.

Field name	Field code	Example	Description and Notes
Date created	DCRE	dcre(20070112) dcre(<20160101)	The date on which the information provider created the document.
Date revised	DREV	drev(20160825) drev(>=20160101)	The date on which the information provider revised the document.
Document text			See Text
Document title			See Title
Document type	DTYPE	dtype(report)	All document types in AdisInsight: Drugs are reports.
Drug name			See Title
Drug status	DST	dst(active)	There are two drug status types - active and inactive - indicating whether the drug is in active development or not.
Drug synonym	SYN	syn(AG14699) syn(rupacarib camsylate)	Synonyms, lab codes and other names by which the drug is known may appear here in the synonym field. They are searchable with SYN and also with the Substance field code SUBST.
First available	FAV	fav(2012-08-02)	This indicates the first time the record was loaded onto Dialog. It will not change regardless of how many times the record is subsequently reloaded, as long as the accession number does not change.
From database[2]	FDB	su(azepines) AND fdb(adisranddinsight) su(azepines) AND fdb(10000126)	Useful in multi-file searches to isolate records from a single file. FDB cannot be searched on its own; specify at least one search term then AND it with FDB.
Generic name	GN	gn(rucaparib)	The generic name of the drug is also searchable using the Substance search field SUBST.
Highest phase[1]	HP	hp(preregistration)	The highest phase of development the drug has reached anywhere in the world
History	HI	hi("scientific update") hi(20160823) hi(2016-08-23)	The history includes date, update, update date and brief details of milestones in the drug's development.
Indication[1]	IND	ind("breast cancer")	The drug's indications are listed here. They can be searched on their own in the IND field, and also in combination with country and phase in the PHS field. A search of SU also includes in the indication.

Field name	Field code	Example	Description and Notes
Licensee	LCO	lco(pfizer)	The licensee company is also searchable using the Company field code CO.
Licensing information	LIC	lic(europe)	Information on the licensing availability of the drug including phases, included and excluded regions, dates and contacts may be present in some documents.
Mechanism of action[1]	MEC	mec(poly adp ribose polymerase inhibitors)	The drug's mechanism of action. Search with both MEC and SU.
Milestones	MRE	mre("priority review status" NEAR ovarian)	Displayed in the History of Drug Development table in the text.
Molecular formula	MF	mf(c19h18fn3o)	The drug's molecular formula
Origin of substance	OS	os(yes) os(no)	Fixed combination: yes or no
Originator	DOR	dor("cancer research uk")	The originator of the drug is searchable with both DOR and the Company field code CO.
Orphan drug	ORD	ord("ovarian cancer")	If the drug has orphan status, the indication, region and company are presented here.
Pharmacokinetics	PK	pk("t (1/2) beta (h)")	Pharmacokinetics data of the drug
Phase of development[1]	PHS	phs(discontinued) phs("phase iii" LNK belgium LNK "ovarian cancer") phs(suspended -- ireland -- melanoma)	The drug's phases of development, along with country, indication, route of administration, formulation, notes and indication of fast-track status are presented in the Development Phases table in the text. Use LNK or -- to link terms in the same row
Publication date	PD	pd(20160826) pd(>=20150401) pd(20160101-20160901)	Search exact dates or ranges
Publication title	PUB	pub("adisinsight: drugs")	The Publication title for all documents is "AdisInsight: Drugs".
Publication type	PSTYPE	pstype(report)	All documents have the publication type "Report".
Publication year	YR	yr(2016) yr(2013-2016) yr(>2014)	Exact years and ranges are searchable

Field name	Field code	Example	Description and Notes
References	REF	ref(plummer LNK temozolomide)	Includes cited authors, source information, language, country when known and in the case of references to trials, the accession number of the relevant document in *AdisInsight: Trials*.
Cited author	CAU	cau(fong)	
Cited title	CTI	cti("CTLA-4 blockade")	
Cited publication title	CPUB	cpub("clinical cancer research")	
Cited publication year	CYR	cyr(2007)	
Cited volume	CVO	cvo(13)	
Route of administration[1]	RO	ro(iv)	Search the route of administration with both RO and SU.
Subject[1]	SU	su(azepines) su("small molecules")	These are broad terms mainly describing the class of drug. SU also searches the Indication, Route of administration and Mechanism of action fields.
Substance[1]	SUBST	subst(8-fluoro-5- 4-methylamino methyl phenyl -2,3,4,6-tetrahydro-1h-azepino 5,4,3-cd indol-1-one) subst(8-fluoro azepino)	The chemical name of the drug. Remove parentheses and brackets when searching the full name. Parts of chemical names are also searchable. SUBST also searches the CAS Registry number, and Trade name, Synonym and Generic name fields.
Text	TX, FT	tx("small molecule inihbitor" NEAR parp)	The full text of the report. Use proximity and/or Boolean operators to narrow search results. Use double quotes to specify an exact phrase.

Field name	Field code	Example	Description and Notes
Therapeutic classification[1]	TC	tc(antineoplastic*) tc(L1)	Both the EPhMRA and the WHO ATC therapeutic classifications are included. A broad heading and an alpha-numeric code are provided for each class of drug.
Title	TI	ti(rucaparib)	The title of the report. This is usually the generic name of the drug discussed in the report.
Trade name[1]	TN	tn(relistor)	The drug's trade name, when available, is presented here. It is also searchable using the Substance field code, SUBST.
Updated	UD	ud(2020) ud(2020-09-01)	The date on which documents were added or revised in Dialog, to incorporate changes by the information provider.

[1] A Lookup/Browse feature is available for this field in the Advanced Search fields drop-down or in Browse Fields.
[2] Click the "Field codes" hyperlink at the top right of the Advanced Search page. Click "Search syntax and field codes", then click on "FDB command" to get a list of database names and codes that can be searched with FDB.

In addition to ***Search Fields***, other tools available for searching are ***Limit Options***, ***Browse Fields***, ***"Narrow Results By" Limiters*** and ***Look Up Citation***. Each is listed separately below. Some data can be searched using more than one tool.

Limit Options

Limit options are quick and easy ways of searching certain common concepts. Check boxes are available for:

Full text, Drugs with a tradename, Documents with images

Short lists of choices are available for:

Phase and **Highest phase**

Date limiters are available in which you can select single dates or ranges for **Publication date, Date created, Date revised,** and **Updated**.

Browse Fields

You can browse the contents of certain fields by using Look Up lists. These are particularly useful to validate spellings or the presence of specific data. Terms found in the course of browsing may be selected and automatically added to the Advanced Search form. Look Up lists are available in the fields drop-down and in the search options for:

Therapeutic classification, Indication, Mechanism of action, Company

and in the fields drop-down only for:

Subject, Substance, Trade name

"Narrow Results By" Limiters

When results of a search are presented, the results display is accompanied by a list of "Narrow results by" options shown on the right-hand panel. Click on any of these options and you will see a ranked list showing the most frequently occurring

terms in your results. Click on term(s) to include or exclude and apply them to ("narrow") your search results. "Narrow results by" limiters in Adis R&D Insight include

Full text, Therapeutic classification, Highest phase, Company, Mechanism of action, Indication, Publication date

Notes

Excel Custom Export Fields

If you choose to export your data in Excel (XLS) you have the option to use a custom format to output only the fields you need. Dialog shows ALL fields for ALL databases in the custom pick list – not just the ones that are appropriate to this database. The following lists only those fields that may appear in the *AdisInsight: Drugs* database.

Field Name	Detail
Accession Number	Provider's unique record identifier
Article Type	Same for all records
CAS Registry Number	CAS Registry Number
Cited References	See References
Company Information	Supports One-to-Many; the following fields will also be output if you select *Multiple rows per item by: Company Information*
• Company Information – Name	
• Company Information – Type	
• Company Information – Role	
• Company Information – Country/Region	
Database	
Date Created	
Date Revised	
Document Type	Same for all records
Document URL	
Drug Name	See Title
Drug Status	
Drug Synonym	
First Available	
Generic Name	
Indication	
Language	
Language Of Summary	
Licensing Information	
Mechanism Of Action	
Molecular Formula	
Origin Of Substance	
Orphan Drug	
Phase Of Development	Supports One-to-Many; the following fields will also be output if you select *Multiple rows per item by: Phase Of Development*
• Phase Of Development – Phase	
• Phase Of Development – Country/Region	
• Phase Of Development – Indication	
• Phase Of Development – Route Of Administration	
• Phase Of Development – Formulation	
• Phase Of Development – On Fast Track	

• Phase Of Development – Qualifiers And Comments	
Phase Of Development (Highest)	
Publication Date	
Publication Year	
Publication Title	Same for all records
Publication Type	Same for all records
References	Supports One-to-Many; the following fields will also be output if you select *Multiple rows per item by: References*
• Cited Author	
• Cited Publication Title	
• Cited Publication Date	
• Cited Title	
• Cited Volume	
Route Of Administration	
Source Attribution	Same for all records
Source Type	Same for all records
Store ID	Dialog's internal unique record identifier
Subject	
Substance	
Therapeutic Class (EPhMRA)	
Therapeutic Class (WHO)	
Title	The name of the drug
Tradename	
Updates	

Document Formats

Document Format	Fields	Online	Export / Download
Brief view	Title and Publication date	✓	
Detailed view	Same as Brief view plus a thumbnail of image if available	✓	
KWIC (Keyword in Context)	Detailed view plus all occurrences of your search terms, highlighted within the fields where the terms occur	✓	✓
Preview	Title, Publication title, Publication date, Subject terms	✓	
Brief citation	Title, Publication date and partial indexing	✓	✓
Full text	Complete record	✓[1]	✓
Custom	Choose the fields you want		✓[2]

[1] In Online-view mode, Dialog gives access to two Document Formats only: *Brief citation*, and the 'most complete' format available. The most complete format in AdisInsight: Drugs is either *Full text* or *Full text + graphics*

[2] Custom export/download format is available in the following mediums only: HTML, PDF, RefWorks, RTF, Text only, XLS.

Terms & Conditions

Contact**: Dialog Global Customer Support**
Email: Customer@dialog.com
Within North America **1 800 334 2564**
Outside North America **00 800 33 34 2564**